Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

Affiliations

• ¹ Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
• ² Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, UMR ICAN 1166, Sorbonne Universités, UPMC Univ Paris 06, Faculty of Medicine, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France.
• ³ Department of Medicine and Robert H Lurie Cancer Center, Northwestern University, Chicago, IL, USA.
• ⁴ AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, UMR ICAN 1166, Sorbonne Universités, UPMC Univ Paris 06, Faculty of Medicine, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France.
• ⁵ Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: douglas.b.johnson@vanderbilt.edu.